What Management Said
Read the full Q2 2026 transcript ↗Our second quarter results and updated full year 2026 outlook demonstrate continuing progress toward delivering more consistent and dependable performance. The pricing, benefit design, and market actions we've taken over the past year have been central in supporting our second quarter results and improved full-year outlook. We now expect full-year Medicare Advantage enrollment to decline by approximately 1.1 million and Medicare margins to finish 2026 above 3%. We will continue to support program and margin stability through actions including benefit adjustments and selective changes in market participation.
At this distance, commercial margin recovery will remain a focus area longer than originally anticipated. Second, home health initiatives to better support patients as they return home, where they can be managed more comfortably and effectively, have reduced readmissions. I will briefly review second quarter results, discuss expectations for the remainder of the year as we refresh our 2026 guidance. Overall, the quarter and full-year outlook reflect improved performance across our businesses, with notable improvements in UnitedHealthcare and Optum Health.
UnitedHealth Group reported adjusted earnings per share of $6.38, compared to $4.08 in the prior year. Total revenues were $112 billion, largely consistent with the prior year, while operating earnings of $8 billion grew 55% year-over-year. Operating cash flows in the quarter were approximately $11 billion, or 1.9x net income, reflecting timing of substantial government payments and strong earnings. This provides capital to strengthen the balance sheet, invest in growth, and return value to shareholders.
What went well
- UnitedHealth Group reported adjusted EPS of $6.38, up sharply from $4.08 a year earlier, with operating earnings of $8 billion growing 55% year-over-year on ~$112 billion of revenue.
- UnitedHealthcare's Medicare Advantage performance exceeded expectations, with better-than-anticipated membership retention and full-year Medicare margins now expected to finish above 3%.
- The reported medical care ratio improved to 86.7% (from 89.4% a year earlier), including $860 million of net favorable prior-period development.
- Optum Health showed building momentum as it re-centered on integrated value-based care, with a ~10% reduction in hospitalizations from transitions-of-care support and patient access expanded by ~200,000 hours.
- Optum Rx transparency initiatives resonated (high-90s retention), with a new monthly per-member-fee model and 95%+ of clients expected on 100% rebate pass-through by end of 2026.
- Operating cash flow was ~$11 billion (1.9x net income), the debt-to-capital ratio improved to 41.2% (toward ~40% by year-end), and the company raised its 2026 buyback target to at least $5 billion (from $2.5 billion).
What went wrong
- Commercial benefits cost trends remained stubbornly high, running modestly above the prior 11% level, and commercial margin recovery will now take longer than originally anticipated (past 2027).
- The ineffective Independent Dispute Resolution (IDR) process under the No Surprises Act plus more aggressive provider coding/billing are adding ~100 basis points of commercial cost trend.
- Medicaid margins are expected to remain pressured for 2026 (within the -1% to -1.7% range) as reimbursement rates (~6-7% annualized) still lag elevated medical trend.
- The operating cost ratio rose to 12.7% (from 12.3%) and is expected at the higher end of the range due to investments in people, communities and AI.
- The refreshed full-year adjusted EPS guidance of $19.50-$20.00 sits well below prior-year levels, reflecting a reset year after 2024-2025 challenges.
- Star ratings remain a challenge (2026 industry scores at a decade low), with management declining to speculate on 2026/2027 outcomes amid industry litigation.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Full-year adjusted EPS | FY2026 | $19.50-$20.00 (slightly more earnings in Q3 than Q4) |
| UnitedHealthcare operating earnings | FY2026 | at least $12 billion (raised) |
| Optum Health operating earnings | FY2026 | at least $2.2 billion (raised) |
| Full-year medical care ratio | FY2026 | 88.1% +/- 25 basis points |
| Full-year share repurchases | FY2026 | at least $5 billion |
| Medicare medical cost trend | FY2026 | expected below ~10% (point estimate to be updated next call) |
| Medicaid margins | FY2026 | -1% to -1.7% (remain pressured) |
| Long-term EPS growth algorithm | long-term | 13%-16% reaffirmed from the $19.50-$20.00 stepping-off point |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Adjusted EPS | $6.38 (from $4.08) | Product and portfolio actions over the prior 12 months plus more focused management disciplines. |
| Total revenue | $112 billion (~flat) | Broadly consistent with the prior year across the enterprise. |
| Operating earnings | $8 billion (+55%) | UnitedHealthcare and Optum Health improvement from portfolio actions and management disciplines. |
| Medical care ratio | 86.7% (from 89.4%) | Pricing/benefit actions plus $860M of net favorable prior-period development. |
| Medicare Advantage | margins to finish above 3% | Better retention, disciplined benefit design, network curation and a favorable respiratory season. |
| Commercial benefits | cost trend modestly above 11% | IDR/No Surprises Act exploitation and higher provider coding intensity. |
| Operating cost ratio | 12.7% (from 12.3%) | Targeted investments in technology, AI, care delivery and the United Health Foundation. |
| Operating cash flow | ~$11 billion (1.9x net income) | Timing of government payments and strong earnings. |
| Debt-to-capital | 41.2% (from 44.1%) | Capital discipline; on track to ~40% by year-end. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Turnaround / earnings reset | 2024-2025 challenges | One year into Hemsley's return and team restructuring, management describes stronger, more consistent performance disciplines, calls the $19.50-$20.00 base durable quality of earnings, and reaffirms the 13-16% long-term growth algorithm off that stepping-off point. | — |
| Medicare Advantage trend & bids | ~10% 2026 trend assumption (7.5% core + fee schedule + unknowns) | Trend running below planning assumptions (favorable claims, lighter flu/respiratory season, unused risk accommodation) but not an inflection; 2027 bids planned off current experience with no meaningful deviation from elevated core trend. | — |
| Commercial cost-trend pressure | ~11% trend, margin recovery by 2027 | Trend modestly above 11%; ineffective IDR (40% of claims ineligible, 60% of arbitration from five entities, arbiter awards averaging 11x Medicare up to 30x) plus provider coding intensity extend margin recovery past 2027 toward the historic 7%+ target. | — |
| Optum Health value-based care re-centering | Restructuring | Improved care management (transitions-of-care cutting hospitalizations ~10%, home-health and rural expansion), regional/national operating focus, ambient-listening AI at 70% of employed providers (>90% by year-end), and earlier 2027 payer benefit-planning collaboration; margins expected to steadily improve. | — |
| Optum Rx transparency | Rebate pass-through commitment | New monthly per-member-fee model with full PBM/GPO fee transparency; high-90s retention; 95%+ of clients on 100% rebate pass-through by end 2026, ahead of the end-2027 commitment. | — |
| AI as enterprise operating infrastructure | Early AI investment | Reimagining the entire enterprise: near-100% of provider/consumer interactions use AI, complex-claims automation, 96% first-pass digital prior-auth approval (humans decide denials), ambient documentation cutting clinician burnout ~90%, and commercializing internal use cases via Optum Real (~half a million prior auths processed); benefits accelerating into 2027-2028. | — |
| Prior-authorization / experience modernization | High administrative burden | Committed to eliminating 30% of prior-auth volume and nearly two-thirds of pediatric prior-auth requirements by year-end, and processing 80% of prior auths in real time by end-2027, reducing abrasion for providers and patients. | — |
| Medicaid & Optum Insight | Rate lag / reinvestment | Medicaid working with states to close the rate-vs-trend gap (early behavioral-health improvement) with margins still pressured; Optum Insight slightly ahead in Q2 (AI efficiencies plus pulled-forward client volume) on a multi-year reinvestment path with full-year guidance intact. | — |
Q&A Summary
Justin Lake (Wolfe) asked about Medicaid margins and the magnitude/margin trajectory of commercial cost-trend pressure.
Cotton said Medicaid Q2 was in line with margins within the -1% to -1.7% range and ~6-7% annualized rate impacts still lag trend; Kueter said commercial trend is modestly above 11% (IDR adding ~100 bps, plus coding intensity and specialty pharmacy), delaying full commercial margin recovery past 2027 toward the historic 7%+.
A.J. Rice (UBS) asked where the turnaround stands and whether the 13-16% growth trajectory is sustainable.
Hemsley said the company will 'remain restless,' that the mission is broader than a growth rate, and that he never stopped believing in the 13-16% algorithm (aided by productivity and technology), which UnitedHealth can sustain despite recent challenges.
Stephen Baxter (Wells Fargo) asked where Medicare cost trend sits versus 2025 and versus the finalized bids.
Noel said trend remains very high historically but below planning assumptions across UHC, not an inflection; Hunter detailed the 2026 build (elevated 2025 core utilization plus fee-schedule and unknown-risk accommodations) and said lighter flu/respiratory experience and unused risk accommodation, plus targeted actions, drove the favorable variance, with 2027 planned off current experience.
Kevin Fischbeck (Bank of America) asked whether the 2026 baseline should be adjusted for prior-period development or MA rebids.
DeVeydt said the $19.50-$20.00 is the right stepping-off point (reflecting PPD) with durable, quality earnings, and reaffirmed the 13-16% growth algorithm from there.
Lisa Gill (JPMorgan) asked how much investment spending is one-time and the benefit into 2027.
DeVeydt said the foundation investments (now ~$1 billion) and other spend are not viewed as one-time as the company builds its foundation, that the underlying run-rate is durable, and that nothing should be carved out in either direction from the $19.50-$20.00 base, with commercial recovery a future tailwind.
Andrew Mok (Barclays) asked why IDR-driven commercial costs are accelerating now and whether it is priceable.
Kueter said the ineffective IDR process has accelerating dispute volume exposing its deficiencies (40% of claims ineligible, 60% of arbitration from five entities, awards averaging 11x Medicare up to 30x, with state variations), calling for reform as it burdens employers.
Ann Hynes (Mizuho) asked for the Medicare cost-trend point estimate versus the original ~10%/7.5% build.
Noel said, anchoring to 7.5% (2025) restated somewhat favorably, trend is a little lower than planning with unused unknown-risk accommodation, but declined a new point estimate until next call given the year is only half done.
Lance Wilkes (Bernstein) asked about Optum Health value-based/capitated margins and improvement actions.
Nelson said first-half value-based margins were strong and slightly better than expected on care-management and operating-performance gains (transitions-of-care cutting inpatient ~10%, +200,000 patient hours, +5% satisfaction), with strategically aligned payer contracting largely complete for 2027.
George Hill (Deutsche Bank) asked about outpatient surgical volumes and Optum Insight cadence.
Nelson said surgical volumes are pacing in line at higher-value ASC sites (~a third of hospital cost) with earnings/volumes/productivity in line to slightly better; Dadlani said Optum Insight was slightly ahead on AI-driven execution and some pulled-forward client volume, remaining on full-year guidance.
Erin Wright (Morgan Stanley) asked whether AI can drive upside to long-term margin targets.
Management framed AI as core operating infrastructure being applied across UHC (near-100% of interactions, complex-claims automation, real-time underwriting), Optum (ambient documentation, 96% first-pass digital prior-auth, ~40% faster case summaries) and corporate functions, with compounding benefits accelerating into 2027-2028 and commercialization via Optum Real.
Whit Mayo (Leerink) asked about Star ratings expectations and industry lawsuits.
Hunter declined to speculate on 2026/2027 Star outcomes given the cycle and litigation, noted 2026 industry scores are at a decade low, said UnitedHealth prefers to partner with CMS on solutions for program stability, and reaffirmed heavy investment in the quality agenda.
David Windley (Jefferies) asked why Optum Health margins held up sequentially and about the PDR bridge.
Nelson cited a shift of some restructuring into the second half plus continued investments and respect for elevated trend as reasons the usual seasonal decline was muted; DeVeydt said the declining PDR adjustment reflects divested items (moving both the charge and its benefit) and does not affect durable margins.
More on Unitedhealth Group Inc
Reported 2026-07-16 · figures from the Unitedhealth Group Inc Q2 2026 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.